Medpace Holdings, Inc.
NASDAQ:MEDPMedical - Diagnostics & Research
-$4.51 today
- Market cap
- $18.09B
- Beta
- 1.18
- P/E (TTM)
- 28.2
- EPS (TTM)
- $16.19
Volume 0.21M
Average 0.36M
MEDP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Medpace Holdings, Inc.NASDAQ: MEDP
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $137.46M rose 23.7% year over year, ahead of the +19.6% change in trailing-twelve-month net income. Sequentially, it rose 13.3% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.
Context
- Net income amounted to 17.8% of revenue in FY2025, down 1.3 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of $534.59M (+18.5%) for the fiscal year ending Dec 2026, a step up from the +11.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $137.46M+13.3% QoQ
- Last fiscal yearDec 2025
- $451.12M+11.6% YoY
- LTMSep 2026
- $517.83M+19.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.7% | +1.5% | -22.2 pp |
| 1 year | +11.6% | +18.5% | +6.9 pp |
| 3-year CAGR | +22.5% | +13.2% | -9.3 pp |
| 5-year CAGR | +12.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 451.12M USD
- Year-over-year change
- +11.6%
- 4-year CAGR
- +25.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 451.12M | +11.6% |
| FY2024 | 2024-12-31 | 404.39M | +43.0% |
| FY2023 | 2023-12-31 | 282.81M | +15.3% |
| FY2022 | 2022-12-31 | 245.37M | +34.9% |
| FY2021 | 2021-12-31 | 181.85M | — |
Net Income vs competitors
How MEDP compares with its peers on the latest reported figures
- MEDP's LTM Sep 2026 net income of $517.83M is the 2nd largest of the 5 companies compared; the peer median is $81.51M.
- Its year-over-year change of +19.6% is the 2nd highest of 5, against a peer median of -28.6%.
- Net income amounts to 18.2% of revenue for MEDP, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.38B | +11.5% | +7.6% | 8.1% | |
| LTM Sep 2026 | $517.83M | +19.6% | +22.5% | 18.2% | |
| LTM Jun 2026 | $248.21M | -68.7% | -23.2% | 3.0% | |
| LTM Jun 2026 | $236.56M | +264.6% | — | 5.9% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $85.2M | -91.8% | — | 3.2% |
| Peer median (excluding MEDP) | $81.51M | -28.6% | -7.8% | 4.5% | |
Competitors are the stored peer set for MEDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M |
| Depreciation & Amortization | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M |
| Deferred Income Tax | (37.11M) | (23.01M) | (25.12M) | (26.63M) | 80.77M |
| Stock-Based Compensation | 14.47M | 21.41M | 20.52M | 25.51M | 34.79M |
| Change in Working Capital | 66.71M | 106.06M | 106.49M | 157.18M | 96.28M |
| Accounts Receivables | (24.98M) | (66.92M) | (48.28M) | 2.24M | (106.22M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.87M | 6.43M | 1.05M | (2.97M) | 2.63M |
| Other Working Capital | 89.82M | 166.54M | 153.72M | 157.9M | 199.86M |
| Other Non-Cash Items | 16.3M | 15.89M | 22.35M | 19.12M | 22.14M |
| Operating Cash Flow | 263.33M | 388.05M | 433.37M | 608.82M | 713.22M |
| Capital Expenditures | (28.27M) | (36.88M) | (36.65M) | (36.55M) | (31.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.09M) | (1.86M) | 2.02M | 8.24M | 216K |
| Investing Cash Flow | (31.36M) | (38.74M) | (34.63M) | (28.31M) | (31.14M) |
| Debt Repayment | 0 | 50M | (50M) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 57M |
| Common Stock Repurchased | (62.1M) | (847.85M) | (144.02M) | (169.87M) | (917.39M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 17.64M | 22.07M | 11.38M | 15.86M | 0 |
| Financing Cash Flow | (44.45M) | (775.78M) | (182.64M) | (154.01M) | (860.39M) |
| Effect of Forex Changes | (3.97M) | (6.57M) | 1.08M | (2.51M) | 5.92M |
| Net Change in Cash | 183.54M | (433.04M) | 217.18M | 423.99M | (172.39M) |
| Free Cash Flow | 235.06M | 351.17M | 396.73M | 572.27M | 681.87M |
Medpace Holdings, Inc.
NASDAQ:MEDP
Intrinsic Alpha fair value
Locked
Current Price
$646.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.